Keros Therapeutics Sees Unusually High Options Volume (NASDAQ:KROS)

Keros Therapeutics, Inc. (NASDAQ:KROS) was the target of unusually large options trading on Thursday. Stock investors purchased 2,688 call options on the company. This is an increase of approximately 3,532% compared to the typical daily volume of 74 call options.

Keros Therapeutics Stock Performance

NASDAQ:KROS opened at $18.43 on Friday. The company has a market capitalization of $746.54 million, a PE ratio of -3.54 and a beta of 1.20. Keros Therapeutics has a fifty-two week low of $15.67 and a fifty-two week high of $73.00. The company has a 50 day simple moving average of $59.95 and a two-hundred day simple moving average of $52.83.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million for the quarter. During the same period in the previous year, the company earned ($1.33) earnings per share. The firm’s revenue was up 4750.0% compared to the same quarter last year. Research analysts predict that Keros Therapeutics will post -5.26 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday. Bank of America reduced their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, September 12th. Wells Fargo & Company upped their price objective on Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday. Jefferies Financial Group initiated coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating on the stock. Finally, Guggenheim reissued a “buy” rating and issued a $102.00 target price (up previously from $96.00) on shares of Keros Therapeutics in a report on Wednesday, December 4th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $95.22.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in Keros Therapeutics by 6.8% in the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after purchasing an additional 46,041 shares in the last quarter. Barclays PLC increased its position in Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after buying an additional 35,022 shares in the last quarter. Wellington Management Group LLP acquired a new position in Keros Therapeutics during the 3rd quarter worth approximately $868,000. Point72 DIFC Ltd boosted its holdings in Keros Therapeutics by 9.8% in the third quarter. Point72 DIFC Ltd now owns 19,255 shares of the company’s stock worth $1,118,000 after acquiring an additional 1,715 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in shares of Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after acquiring an additional 577,220 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.